Biomarkers · Nutritional

Serum Lycopene

Higher values go with lower risk of death. Not measured in our NHANES panel. The curve is drawn from the published study (source below).

Serum Lycopene and risk of death

Published curve higher than the NHANES fitNHANES fit higher

Risk of death relative to the curve's reference value, drawn from the published study (source below).

Published risk of death0.75×highest vs lowest category of circulating lycopene concentration (95% CI 0.54–0.97) · Meta-analysis of prospective observational studies of antioxidants and all-cause mortality in the general population (41 studies overall, n=507,251)

Serum Lycopene by age and sex

Each bar runs from the 5th to the 95th percentile, the darker part from the 25th to the 75th, and the tick is the median. Not a reference range or a target.

The percentiles as a table

Each row is one sex and age band: the values below which 5%, 25%, 50%, 75% and 95% of people fall (ug/dL), from the survey named in the row. Not a reference range or a target.
Sex	Age	5th	25th	Median	75th	95th	n	Cycle / source
All	20-39	17.5	29.0	38.6	50.1	70.1	1,345	NHANES 2017-2018
All	40-59	15.8	28.9	41.2	55.2	79.2	1,471	NHANES 2017-2018
All	60+	10.7	21.3	32.8	45.5	72.6	1,821	NHANES 2017-2018
All	all	14.0	26.4	37.7	50.6	74.0	4,637	NHANES 2017-2018
Men	20-39	20.2	30.1	40.7	52.4	74.2	645	NHANES 2017-2018
Men	40-59	15.7	30.8	43.3	58.2	82.1	690	NHANES 2017-2018
Men	60+	11.7	20.7	32.4	47.1	69.4	920	NHANES 2017-2018
Men	all	14.8	27.7	38.6	52.5	77.2	2,255	NHANES 2017-2018
Women	20-39	15.1	27.2	37.7	48.0	68.4	700	NHANES 2017-2018
Women	40-59	15.8	26.8	38.8	52.2	76.2	781	NHANES 2017-2018
Women	60+	9.93	21.5	33.4	44.3	73.3	901	NHANES 2017-2018
Women	all	13.3	25.4	36.5	48.6	72.8	2,382	NHANES 2017-2018

What studies found when this marker was changed

They describe what happened in those study groups, not a recommendation. See all catalogued interventions.

Measured changes in Serum Lycopene, study by study

1 effect with a numeric size, each from one study arm: the dot is the reported change, the line its 95% interval where one was given. Green points move the marker the way lower risk of death lies; amber the other way. Study results in the groups studied, not predictions for a person.

Each row is one study: what was changed, the effect it reported on this marker, and the source.
Type	Intervention	Reported effect	Evidence	Source
diet	One 11.5 oz serving of 100% vegetable juice daily (29.4 mg lycopene) for 30 days in patients with heart failure	Plasma lycopene rose from 0.51 to 0.76 umol/L over 30 days (P = .002) vs 0.56 to 0.58 umol/L with usual care	RCT	Biddle MJ, Lennie TA, Bricker GV, et al. Lycopene dietary intervention: a pilot…

What else moves this marker

They describe those study groups, not an individual, and an association is not a cause.

Diseases and conditions

Each row is one study: what it compared and the change it reported in this marker.
What	Effect on the marker	Comparison · population	Source
↓ Oral leukoplakia (men) · male leukoplakia cases vs age/sex-matched controls	ratio 0.68	cases (0.175 umol/L) vs controls (0.257 umol/L), ratio of means · Japanese screening cohort (Tokoname); 48 leukoplakia cases (38 men), 4 matched controls each	case control · PMID 10964055

Sources

Risk curve: Jayedi 2018 (PMID 30239557): all-cause RR 0.75 (0.54-0.97) highest vs lowest category of circulating lycopene concentration. Scaled to US values (NHANES).
Jayedi et al. Dietary Antioxidants, Circulating Antioxidant Concentrations, Total Antioxidant Capacity, and Risk of All-Cause Mortality: A Systematic Review and Dose-Response Meta-Analysis of Prospective Observational Studies. Advances in nutrition (Bethesda, Md.). 2018;9:701-716.

Map Serum Lycopene against another biomarker.

Map Serum Lycopene against another marker